SCHEMBL7401045

SCHEMBL7401045

O=C(CC1OCCc2cc(Br)ccc21)N1CCN(c2ccc(Cl)c(Cl)c2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.46
MAPT P10636 4/20 0.43
HTT P42858 4/20 0.43
MAPK1 P28482 1/20 0.43
ADAMTS5 Q9UNA0 2/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
USP2 O75604 1/20 0.41
ALOX15 P16050 1/20 0.41
HSD17B10 Q99714 1/20 0.41
HTR1D P28221 5/20 0.40
SLC6A4 P31645 1/20 0.40
MEN1 O00255 2/20 0.40
ALDH1A1 P00352 2/20 0.40
KMT2A Q03164 2/20 0.40
IGF1R P08069 1/20 0.40
DRD2 P14416 3/20 0.40
HTR2A P28223 3/20 0.40
HTR1A P08908 2/20 0.40
DRD4 P21917 1/20 0.40
LMNA P02545 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7404888 0.90 AKR1C3 (0.46) MAPTSMN1; SMN2HTR1DMEN1KMT2A
SCHEMBL7398102 0.86 HTR1D (0.44) MAPTHTTHTR1DSLC6A4MEN1
SCHEMBL7403199 0.86 MAPT (0.51) MAPTSMN1; SMN2HTR1DSLC6A4DRD2
SCHEMBL8591793 0.85 HTR1D (0.43) MAPTHTTMAPK1SMN1; SMN2ALOX15
SCHEMBL8591794 0.85 HTR1D (0.43) MAPTHTTMAPK1SMN1; SMN2ALOX15
SCHEMBL8591792 0.84 DRD2 (0.57) MAPTHTTMAPK1SMN1; SMN2ALOX15
SCHEMBL8592418 0.84 AKR1C3 (0.46) MAPTHTTADAMTS5USP2HSD17B10
SCHEMBL8590585 0.84 DRD2 (0.57) MAPTHTTMAPK1SMN1; SMN2ALOX15
SCHEMBL8592415 0.84 AKR1C3 (0.46) MAPTHTTADAMTS5USP2HSD17B10
SCHEMBL8590591 0.84 DRD2 (0.57) MAPTHTTMAPK1SMN1; SMN2ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6133446-A Heterocyclic compounds for the treatment of CNS and cardiovascular disorders PHARMACIA & UPJOHN COMPANY (US) 2000-10-17 US disclosed
EP-0737189-B1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CNS AND CARDIOVASCULAR DISORDERS UPJOHN CO (US) 1999-07-28 EP disclosed
EP-0737189-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CNS AND CARDIOVASCULAR DISORDERS PHARMACIA & UPJOHN COMPANY (US) 1996-10-16 EP disclosed
WO-1995018118-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CNS AND CARDIOVASCULAR DISORDERS THE UPJOHN COMPANY (US) 1995-07-06 WO disclosed